Evidence map›Paper›PMID 37554170›Full record

ArticleFrontiers in oncology2023

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma.

Alicia Bao, Qiuhong Zhao, Ruchi Kudalkar, Jose Rodriguez, Nidhi Sharma, Naresh Bumma, Srinivas S Devarakonda, Abdullah M Khan, Elvira Umyarova, Ashley E Rosko and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alicia BaoThe Ohio State University, College of Medicine, Columbus, OH, United States.
Qiuhong ZhaoDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Ruchi KudalkarThe Ohio State University, College of Medicine, Columbus, OH, United States.
Jose RodriguezThe Ohio State University, College of Medicine, Columbus, OH, United States.
Nidhi SharmaDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Naresh BummaDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Srinivas S DevarakondaDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Abdullah M KhanDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Elvira UmyarovaDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Ashley E RoskoDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Don BensonDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Francesca CottiniDepartment of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, United States.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

In transplant-eligible patients who undergo upfront autologous stem cell transplant (ASCT) for multiple myeloma (MM), standard practice is to treat with six to eight cycles of induction therapy followed by high-dose chemotherapy with ASCT. A gap between the end of induction and the day of ASCT exists to allow stem cell mobilization and collection. Despite attempts to limit the length of this interval, we noticed that some patients experience interval progression (IP) of disease between the end of induction therapy and the day of ASCT. We analyzed 408 MM patients who underwent ASCT between 2011 and 2016. The median length of the interval between end of induction and ASCT was 38 days. We observed that 26% of patients in the entire cohort and 23.6% of patients who received induction with bortezomib-lenalidomide-dexamethasone (VRD) experienced IP. These patients deepened their responses with ASCT, independently of induction regimen. In the entire cohort, IP was significantly associated with shorter PFS in the univariable analysis (Hazard Ratio, HR = 1.37,

Indexed as

disease progressionimmune profilingmyelomaoutcomestem cell transplant (SCT)

Identifiers

PMID37554170
PMCPMC10405820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.